hsa-miRNA-548v controls the viscoelastic properties of human cardiomyocytes and improves their relaxation rates.

Cardiology Heart failure Stem cells iPS cells

Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
02 Jan 2024
Historique:
medline: 3 1 2024
pubmed: 3 1 2024
entrez: 2 1 2024
Statut: aheadofprint

Résumé

The impairment of left ventricular (LV) diastolic function with inadequate increase in myocardial relaxation velocity directly results in lower LV compliance, increased LV filling pressures and heart failure symptoms. The development of agents facilitating the relaxation of human cardiomyocytes requires a better understanding of the underlying regulatory mechanisms. We performed a high-content microscopy-based screening in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) using a library of 2565 human miRNA mimics and measured relaxation kinetics via high-computing analyses of motion movies. We identified hsa-miR-548v, a primate specific miRNA, as the miRNA producing the largest increase in relaxation velocities. This positive lusitropic effect was reproduced in engineered cardiac tissues generated with healthy and BRAF T599R mutant hiPSC-CMs, and was independent of changes in calcium transients. Consistent with improvements in viscoelastic responses to mechanical stretch, RNA-sequencing showed that hsa-miR-548v down-regulated multiple targets, especially components of the mechano-sensing machinery. The exogenous administration of hsa-miR-548v in hiPSC-CMs notably resulted in a significant reduction of ANKRD1/CARP1 expression and localization at the sarcomeric I-band. This study suggests that the sarcomere I-band is a critical control center of the ability of cardiomyocytes to relax and a target for improving relaxation and diastolic dysfunction.

Identifiants

pubmed: 38165745
pii: 161356
doi: 10.1172/jci.insight.161356
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Eva Vermersch (E)

Heart Failure Translational Lab, Inserm U970, Paris Cardiovascular Research Center, Paris, France.

Salomé Neuvendel (S)

PARCC, Université Paris Cité, INSERM, Paris, France.

Charlene Jouve (C)

INSERM, Université Paris Cité, INSERM, Paris, France.

Andrea Ruiz-Velasco (A)

PARCC, Université Paris Cité, INSERM, Paris, France.

Céline Pereira (C)

Heart Failure Translational Lab, Université Paris Cité, INSERM, Paris, France.

Magali Seguret (M)

Heart Failure Translational Lab, Université Paris Cité, INSERM, Paris, France.

Marie-Elodie Cattin-Messaoudi (ME)

In vitro pharmacology, Institut de Recherches Servier, Paris, France.

Sofia Lotfi (S)

In vitro pharmacology, Institut de Recherches Servier, Paris, France.

Thierry Dorval (T)

In vitro pharmacology, Institut de Recherches Servier, Paris, France.

Pascal Berson (P)

Cardiovascular and Metabolism Therapeutic Area, Institut de Recherches Servier, Paris, France.

Jean-Sébastien Hulot (JS)

PARCC, Université Paris Cité, INSERM, Paris, France.

Classifications MeSH